XNASCALC
Market cap43mUSD
Jan 07, Last price
3.21USD
1D
0.63%
1Q
-19.69%
IPO
-49.29%
Name
CalciMedica Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
39.26%
Rev. gr., 5y
%
Revenues
0k
Net income
-34m
L-3.51%
CFO
-26m
L+12.46%
Earnings
Mar 26, 2025
Profile
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 12,417 | 33,269 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (12,417) | (33,269) | ||||
NOPBT Margin | ||||||
Operating Taxes | (110) | 2,388 | ||||
Tax Rate | ||||||
NOPAT | (12,307) | (35,657) | ||||
Net income | (34,357) -3.51% | (35,605) -0.60% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 25,445 | 18 | ||||
BB yield | -198.15% | |||||
| Debt | ||||||
Debt current | 203 | |||||
Long-term debt | 5,360 | |||||
Deferred revenue | ||||||
Other long-term liabilities | 2,645 | |||||
Net debt | (11,238) | (33,565) | ||||
| Cash flow | ||||||
Cash from operating activities | (25,730) | (22,879) | ||||
CAPEX | (78) | (2,252) | ||||
Cash from investing activities | 8,884 | 26,958 | ||||
Cash from financing activities | 20,900 | (139) | ||||
FCF | (12,279) | (33,871) | ||||
| Balance | ||||||
Cash | 11,238 | 39,128 | ||||
Long term investments | ||||||
Excess cash | 11,238 | 39,128 | ||||
Stockholders' equity | (146,061) | (142,757) | ||||
Invested Capital | 154,218 | 178,929 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 4,490 | 1,535 | ||||
Price | 2.86 | |||||
Market cap | 12,841 | |||||
EV | 1,603 | |||||
EBITDA | (12,359) | (32,931) | ||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||